Business Context and Reporting Period
This Form 8-K, dated June 10, 2025, is filed by Salarius Pharmaceuticals, Inc. (the "Company") regarding a material amendment to its previously announced merger with Decoy Therapeutics Inc. ("Decoy"). The filing details the execution of a Second Amendment to the Merger Agreement to address significant market condition changes and secure necessary noteholder consents.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period. Key transaction-specific financial terms include:
- Qualified Financing Requirement: The merger closing is conditioned on minimum proceeds of at least $6.0 million from offerings.
- Valuation Adjustment: The Company's relative valuation was reduced from $4.6 million (original agreement) to $2.31 million.
- Ownership Structure: Following the amendment, legacy Salarius stockholders will retain 7.6% of the combined company, while legacy Decoy stockholders will retain 92.4% (calculated on a fully-diluted basis, pre-financing).
- Share Issuance Impact: The number of Common Stock shares underlying the Series A Preferred Stock to be issued to Decoy stockholders will increase by approximately 17 million shares.
Material Changes Versus Prior Period
Significant changes from the original Merger Agreement (January 2025) and Amendment No. 1 (March 2025) include:
- Ownership Dilution: Salarius legacy stockholder ownership decreased from 14.1% (under Amendment No. 1) to 7.6% due to the Company's stock price deterioration.
- Anti-Dilution Protection: New post-closing anti-dilution price protection was added for Series A Preferred Stock holders. If a subsequent dilutive financing of at least $2 million occurs at a price below the Qualified Financing offering price within one year, the conversion ratio will be reset.
- Conversion Restrictions: The Series A Preferred Stock will not convert until the combined company meets Nasdaq initial listing standards and obtains stockholder approval pursuant to Nasdaq listing rule 5635. A provision preventing short sales by preferred stockholders was also added.
Guidance, Outlook, and Risks
Management Commentary and Risks:
- Market Conditions: The amendment was necessitated by substantial deterioration in the Company's Common Stock price, which materially affected the relative valuations underlying the exchange ratio.
- Closing Conditions: The transaction remains contingent upon the Qualified Financing ($6.0 million) and the continued listing of the Company's common stock on Nasdaq.
- Contingencies: The filing notes the necessity of securing consents from Decoy noteholders for the transaction to proceed.
Important Facts for Investor Verification
- Verify the current status of the $6.0 million Qualified Financing requirement.
- Confirm the Company's ability to meet Nasdaq initial listing standards to trigger the conversion of Series A Preferred Stock.
- Review the full text of Amendment No. 2 (Exhibit 2.1) and the Certificate of Designation (Exhibit 2.2) for complete terms regarding anti-dilution mechanics.
- Monitor the Company's stock price trajectory, as further deterioration could impact the final exchange ratio if additional amendments are required.